Related Experiment Video
Updated: Aug 9, 2026
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and
1Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Insights
Donor chimerism in specific immune cells impacts outcomes after allogeneic stem cell transplantation (CST and NST). Lower chimerism levels in CD56+ and CD14.15+ cells correlate with poorer survival, highlighting chimerism
Area of Science:
- Hematology
- Immunology
- Transplantation Science
Background:
- Allogeneic stem cell transplantation (SCT) is a critical treatment for hematological malignancies.
- Donor-type chimerism, the presence of donor cells, is a key indicator of engraftment success.
- Understanding chimerism dynamics in specific cell lineages is crucial for predicting patient outcomes.
Purpose of the Study:
- To investigate donor-type chimerism in distinct immune cell populations (CD3+, CD14.15+, CD56+) after conventional-intensity SCT (CST) and non-myeloablative SCT (NST).
- To correlate chimerism levels with clinical outcomes, including graft-versus-host disease and overall survival.
Main Methods:
- Analysis of donor-type chimerism in CD3+, CD14.15+, and CD56+ cells at specified time points post-transplantation.
- Comparison of chimerism patterns between CST and NST patient cohorts.
- Statistical analysis to determine the association between chimerism levels and clinical endpoints.
Main Results:
- Non-myeloablative SCT (NST) patients and CST patients receiving non-total body irradiation (TBI) regimens showed more mixed chimerism (<90% donor cells) on day 28 compared to TBI recipients.
- NST patients with acute graft-versus-host disease (grade II-IV) frequently exhibited >50% donor chimerism in CD3+ cells on day 14.
- Significantly poorer 1-year overall survival was observed in NST patients with <50% donor chimerism in CD56+ cells on day 14 and in both NST and CST patients with <90% donor chimerism in CD14.15+ cells on day 28.
Conclusions:
- The extent of donor-type chimerism in lineage-specific cells is a significant predictor of outcomes following allogeneic SCT.
- Monitoring chimerism in CD56+ and CD14.15+ cell populations may offer valuable prognostic information for patients undergoing SCT.
- These findings underscore the importance of assessing detailed chimerism profiles for optimizing SCT strategies and patient management.
Abstract:
We analyzed donor-type chimerism in CD3+, CD14.15+ and CD56+ cells from 36 patients who had undergone conventional-intensity allogeneic stem cell transplantation (CST) and 34 patients who had undergone non-myeloablative allogeneic stem cell transplantation (NST) for hematological malignancies. On day 28 after transplantation, all fractions in NST patients and CD3+ cells in CST patients who received a non-total body irradiation (TBI) regimen showed more frequent mixed chimerism (<90% donor cells) than those in patients who had received TBI. NST patients with acute graft-versus-host disease (grade II-IV) frequently showed more than 50% donor-type chimerism in CD3+ cells on day 14 (P=0.029). NST patients with <50% donor-type chimerism on day 14 and with <90% donor-type chimerism on day 28 in CD56+ cells had significantly poor 1-year overall survival (0 vs 91%, P<0.001 and 20 vs 74%, P=0.002, respectively). Both NST and CST patients with <90% donor-type chimerism in CD14.15+ cells on day 28 had significantly poor 1-year overall survival (14 vs 70%, P=0.005 and 0 vs 66%, P=0.002, respectively). Our data show that the extent of donor-type chimerism in lineage-specific cells appears to have an impact on outcome after allogeneic stem cell transplantation.
